Clinical trials: Head
Solid Tumors Harboring NTRK Fusion
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NAVIGATE (NCT02576431)
- Testing
- BAY2757556 (Larotrectinib, Vitrakvi)
- Where
- 98 sites in United States, Argentina and 23 more
- Volunteers
- 215 people
- Sponsor
- Bayer
Pediculosis
Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
A comparative safety and efficacy study of NatrOVA Creme Rinse - 1% versus NIX Creme Rinse, under actual use conditions in subjects 6 months of age or greater who are infested with Pediculosis capitis (human head lice).
- Trial name
- NCT00545753
- Testing
- Spinosad, Permethrin 1%
- Where
- 6 sites in United States
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- ParaPRO LLC
Head and Neck Squamous Cell Carcinoma
Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
Part1: A mutilpe-center, open-label, Phase II clinical trial to evaluate the efficacy and the safety of HLX10 in combination with HLX07 in patients with advanced advanced head and neck tumors.
- Trial name
- NCT04297995
- Testing
- HLX10, HLX07, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Breast Neoplasms, Colorectal Neoplasms
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
- Trial name
- OMNIRAY (NCT07114601)
- Testing
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select…
- Trial name
- NCT04943900
- Testing
- BMS-986416, Nivolumab
- Where
- 19 sites in United States, Argentina and 5 more
- Volunteers
- 67 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer.
- Trial name
- NCT04752215
- Testing
- BI 765049, ezabenlimab
- Where
- 14 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Boehringer Ingelheim
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma, Unknown Primary
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
This is a single-arm, single site, multi-surgeon prospective feasibility study for transoral robot assisted surgery (TORS) with the Versius Surgical System.
- Trial name
- NCT06112535
- Testing
- Versius Surgical System
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- CMR Surgical Ltd
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor
- Trial name
- NCT05099549
- Testing
- AFM24, SNK01
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- NKGen Biotech, Inc.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm
- Trial name
- NCT02952989
- Testing
- SGN-2FF, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT06549816
- Testing
- sigvotatug vedotin
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Hemostasis
Post-Market Evaluation of HEMOBLAST™ Bellows in Open Gynecological, Urological, ENT, Head, Neck, and Vascular Surgeries
A prospective, multi-center, multi-national single arm study to evaluate the performance and safety of HEMOBLAST™ Bellows in open gynecological, urological, ENT and head and neck, and vascular surgery.
- Trial name
- NOBLE-Open (NCT03873168)
- Testing
- HEMOBLAST™ Bellows
- Where
- 9 sites in Austria, France and 1 more
- Volunteers
- 64 people
- Sponsor
- Biom'Up France SAS
Mild Traumatic Brain Injury, Concussion
A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury
This is a Phase IIa, randomized, double-blind, placebo-controlled pilot study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ONP-002 in adults with mild traumatic brain injury (mTBI).
- Trial name
- NCT06870240
- Testing
- Neurosteroid enantiomer
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Oragenics, Inc.
Melanoma, Non-small Cell Lung Cancer
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
This was a single arm, open-label, single center, cohort study to determine the efficacy and safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung carcinoma (NSCLC) and squamous cell cancer…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05117138
- Testing
- AMT-116 CAR-T cells, AMT-253 CAR-T cells
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer
Esophageal Squamous Cell Carcinoma
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression…
- Trial name
- NCT06644781
- Testing
- Ifinatamab deruxtecan, Docetaxel, Paclitaxel
- Where
- 168 sites in United States, Belgium and 15 more
- Volunteers
- 510 people
- Sponsor
- Daiichi Sankyo
Esophageal Squamous Cell Carcinoma
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced esophageal squamous cell carcinoma progressed following treatment with…
- Trial name
- NCT03817567
- Testing
- recombinant anti-EGFR monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sinocelltech Ltd.
Cervical Cancer, Anal Cancer
CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A*02:01+ Subjects HPV16 positive advanced cervical, anal, or…
- Conditions
- Cervical Cancer, Anal Cancer, Head and Neck Cancers, Other Solid Tumors
- Trial name
- NCT06358053
- Testing
- CRTE7A2-01 TCR-T cell therapy
- Volunteers
- 24 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Advanced Cancer
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with…
- Trial name
- NCT02554812
- Testing
- Avelumab, Utomilumab, PF-04518600
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 409 people
- Sponsor
- Pfizer